Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Ada Rephaeli"'
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1244 (2021)
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only A
Externí odkaz:
https://doaj.org/article/e14d77353fc84bfe98af7e22dbc9097a
Autor:
Oula C. Mansour, Abraham Nudelman, Ada Rephaeli, Don R. Phillips, Suzanne M. Cutts, Benny J. Evison
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:773-784
Autor:
Mor Dahbash, Ruti Sella, Elinor Megiddo-Barnir, Yael Nisgav, Nataly Tarasenko, Dov Weinberger, Ada Rephaeli, Tami Livnat
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 3, p 714 (2019)
Choroidal neovascularization (CNV) is a complication of age-related macular degeneration and a major contributing factor to vision loss. In this paper, we show that in a mouse model of laser-induced CNV, systemic administration of Butyroyloxymethyl-d
Externí odkaz:
https://doaj.org/article/17ba746b53be4100a306723f33b8453b
Autor:
Lilach Moyal, Nataly Feldbaum, Neta Goldfeiz, Ada Rephaeli, Abraham Nudelman, Michal Weitman, Nataly Tarasenko, Batia Gorovitz, Leah Maron, Shiran Yehezkel, Iris Amitay-Laish, Ido Lubin, Emmilia Hodak
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146115 (2016)
The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of
Externí odkaz:
https://doaj.org/article/9ab3cb25672a40d497fe1695f1a53697
Autor:
Oula C, Mansour, Abraham, Nudelman, Ada, Rephaeli, Don R, Phillips, Suzanne M, Cutts, Benny J, Evison
Publikováno v:
Cancer chemotherapy and pharmacology. 89(6)
Pixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin's lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone can also generate covalent drug-DNA adduct
Publikováno v:
Pharmaceuticals; Volume 14; Issue 12; Pages: 1244
Pharmaceuticals, Vol 14, Iss 1244, p 1244 (2021)
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 1244, p 1244 (2021)
Pharmaceuticals
We studied the unique inhibitor of the histone deacetylases (HDAC) valproate-valpromide of acyclovir (AN446) that upon metabolic degradation release the HDAC inhibitor (HDACI) valproic acid (VPA). Among the HDAC inhibitors that we have tested, only A
Publikováno v:
European journal of pharmacology. 882
The anticancer prodrug butyroyloxymethyl diethylphosphate (AN-7), upon metabolic hydrolysis, releases the histone deacetylase inhibitor butyric acid and imparts histone hyperacetylation. We have shown previously that AN-7 increases doxorubicin-induce
Autor:
Nataly Tarasenko, Suzanne M Cutts, Don R Phillips, Aida Inbal, Abraham Nudelman, Gania Kessler-Icekson, Ada Rephaeli
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31393 (2012)
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study investig
Externí odkaz:
https://doaj.org/article/dcc0d7c2dbf64f00a5e9eb8a6a71bb84
Autor:
Salvatore Pepe, Alison Cheong, Tina Robinson, Ada Rephaeli, Ruqaya Maliki, Abraham Nudelman, Donald R. Phillips, Alex J. Spurling, Suzanne Margaret Cutts, Sean McGrath, Belinda S. Parker
Publikováno v:
Cancer Research. 81:992-992
Chemotherapy remains as the mainstay systemic therapy for triple negative breast cancer patients since targeted therapies are not suitable for this breast cancer subtype. Among the chemotherapies for triple negative breast cancer, doxorubicin is know
Autor:
Yael Ziv, Lilach Moyal, Nataly Tarasenko, Abraham Nudelman, Emmilia Hodak, Efrat Tal, Ada Rephaeli, Batia Gorovitz, Neta Goldfeiz
Publikováno v:
Investigational New Drugs. 36:1-9
We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. AN-7 synergizes with doxorubicin (Dox), an anthracycline an